Recent work has further solidified this link, demonstrating that protective interventions, such as the administration of glial growth factor 2 (GGF2), exert their beneficial effects on the BBB in stroke models, specifically by upregulating Mfsd2a and thereby suppressing the Cav‐1‐mediated transcytosis pathway [23]. Here, MFSD2A is linked to stroke disorder.